Ovid Therapeutics (OVID) EBIT (2016 - 2026)
Ovid Therapeutics (OVID) posted EBIT of -$17.8 million for Q1 2026, down 45.17% on a QoQ basis from -$12.3 million in Q4 2025, and down 42.2% year-over-year from -$30.9 million in Q1 2025.
Ovid Therapeutics (OVID) EBIT (2016 - 2026) Analysis & Trends
Ovid Therapeutics' EBIT history runs 11 years deep, the most recent figure standing at -$17.8 million for Q1 2026.
- Quarterly EBIT fell 42.2% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$47.7 million (up 16.28% YoY) and the FY2025 annual result came in at -$42.4 million, up 31.42% from the prior year.
- EBIT was -$17.8 million for Q1 2026 at Ovid Therapeutics, down from -$12.3 million in the prior quarter.
- Across five years, EBIT topped out at -$5.1 million in Q2 2025 and bottomed at -$20.5 million in Q2 2024.
- A 5-year average of -$13.9 million and a median of -$13.2 million in 2024 frame the typical range for EBIT.
- Annual changes were most pronounced in 2022 — EBIT plunged 109.21% — and 2025, when it jumped 75.27%.
- Ovid Therapeutics' EBIT stood at -$12.2 million in 2022, then sank by 49.41% to -$18.2 million in 2023, then surged by 41.05% to -$10.7 million in 2024, then slipped by 14.65% to -$12.3 million in 2025, then tumbled by 45.17% to -$17.8 million in 2026.
- Business Quant data shows OVID's EBIT at -$17.8 million in Q1 2026, -$12.3 million in Q4 2025, and -$12.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 973.81 Bn | 973.81 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.51 Bn | 466.72 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.70 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 55.88 Bn | 50.69 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Ovid Therapeutics | 119.41 Mn | -36.11 Mn | - | -17.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.85 Mn |
| Dec 31, 2025 | -12.29 Mn |
| Sep 30, 2025 | -12.52 Mn |
| Jun 30, 2025 | -5.07 Mn |
| Mar 31, 2025 | -12.55 Mn |
| Dec 31, 2024 | -10.72 Mn |
| Sep 30, 2024 | -13.23 Mn |
| Jun 30, 2024 | -20.52 Mn |
| Mar 31, 2024 | -17.42 Mn |
| Dec 31, 2023 | -18.19 Mn |
| Sep 30, 2023 | -12.03 Mn |
| Jun 30, 2023 | -14.17 Mn |
| Mar 31, 2023 | -14.89 Mn |
| Dec 31, 2022 | -12.17 Mn |
| Sep 30, 2022 | -12.80 Mn |
| Jun 30, 2022 | -14.30 Mn |
| Mar 31, 2022 | -16.27 Mn |
| Dec 31, 2021 | -26.35 Mn |
| Sep 30, 2021 | -11.68 Mn |
| Jun 30, 2021 | -14.31 Mn |